Solvay Sa · EURONEXT:SOLB
Solvay Sa — Investor Presentation (November 2004)
12 slides from Solvay Sa's investor presentation, November 2004
Slide 1: Solvay Group Presentation: Transforming Solvay
SOLVAY GROUP PRESENTATION Transforming Solvay November 2004
Slide 2: A strategy applied with determination
Transforming Solvay « A strategy applied with determination » 2 © 2004, SOLVAY S.A November 2004
Slide 3: A strategy applied with determination
A strategy applied with determination w STRENGTHENING OUR LEADERSHIP in all of our activities : from 75% in 2000 to about 85% in 2003 (in sales) w FASTER DEVELOPMENT of PHARMACEUTICALS and HIGH ADDED VALUE ACTIVITIES è through constant development of competitiveness and ability to innovate 3 © 2004,
Slide 4: A group with 3 sectors
a GROUP with 3 sectors w Pharmaceuticals : acceleration of strategy through partnerships with major players and reinforcement of R&D programs w Chemicals : continued reinforcement of leadership and competitiveness through restructuring, rationalizations, acquisitions and partnerships to improve marg
Slide 5: Leadership in our markets
Leadership in our markets SOLVAY is among the leaders for about 85% of its sales (75% in 2000) Market position Europe US World Hormone Therapies • Female 4 2 2 • Male - 1 1 Pharmaceuticals Digestives/Enzymes 1 3 1 Laxatives 4 - 8 Antispasmodics/IBS 1 6 2 Antidepressants N°1 in Japan Vertigo (Ménière
Slide 6: Focus on Competitiveness
Focus on Competitiveness In a more challenging economic environment : w various parts of the organization are examining proposals which will allow them to reduce their principal operating expenses by 20% over the next three years w Industrial restructuring : rationalizations, transfers, acquisitions
Slide 7: Focus on Competitiveness
Focus on Competitiveness The Group actively pursues its objective of improving its productivity è Industrial restructuring, particularly in Chemicals and Plastics Processing mostly non recurring recording of provisions of about EUR 80 million (for the 9 months 2004) 7 © 2004, SOLVAY S.A November 200
Slide 8: Focus on Innovation
Focus on Innovation “Innovation is vital to our Group's future” Objectives within three years : w 1/5 of our revenue should be from products, markets and applications created over the past five years; w One innovative project in two should be generated in interaction with external partners, such as
Slide 9: Focus on Innovation: recent achievements
Focus on Innovation : recent achievements w Pharmaceuticals 4 Partnerships with highly-skilled partners (Wyeth, Bristol Myers Squibb, Quintiles, Hormos, …) to accelerate R&D 4 Launch of new products (e.g. Invivac®, Teveten® Plus, Estrogel®), in particular in the US 4 Positive R&D outcome : submissio
Slide 10: Higher proportion of pharmaceuticals and specialties
Higher proportion of pharmaceuticals and specialties >70% 67% 70% 60% ü Accelerated shift to higher margin 50% Specialties with the acquisition 40% < 30% 33% of Solexis ü More efficient and 30% more competitive 20% Essentials 10% Pharmaceuticals and Specialties 0% Essentials 1995 2003 In % of Group
Slide 11: For further information, visit www.solvay.com
For further information, visit also www.solvay.com 11 © 2004, SOLVAY S.A November 2004
Slide 12: Forward-looking statements
“To the extent that any statements made in this presentation contain contain information that is not historical, these statements are essentially essentially forward- forward -looking. The achievement of forward--looking statements contained in this presentation is subject to risks and uncertainties